Medical Countermeasures
for Bioterrorism and High-Consequence Biological Threats
$500m+
Million in Government Contracts
100%
Domestically Sourced & Produced*
25+ Yrs
Supporting Global Health Security
ANTHIM®
FDA Approved Anthrax Antitoxin
Preparedness
Is Our Mission
A deliberate biological attack can overwhelm healthcare systems, inflict mass casualties, disrupt economies, and compromise military readiness. Since 1998, Elusys has been a trusted U.S. Government partner in biodefense, developing deployable medical countermeasures built for stockpiling, rapid response, and threat neutralization . Our mandate is clear: deter, defend, and treat biological threats before they escalate into national catastrophes.
_0011%201.png)
Defending Tomorrow… Today
Advancing targeted biodefense therapies for strategic government partners through scientific rigor, regulatory expertise, and operational readiness.
ANTHIM®
(obiltoxaximab)
ANTHIM® is Elusys’ monoclonal antibody medical countermeasure designed to bind and neutralize anthrax toxins. Administered in combination with appropriate antibacterial therapy, it addresses inhalational anthrax—widely regarded as the most likely and concerning biological threat to the United States. FDA-approved in 2016 under the Animal Rule and licensed in other global jurisdictions, ANTHIM® has been procured for the U.S. Strategic National Stockpile and other allied government stockpiles around the world.
Newsletter Signup
Be the first to receive the latest news and updates.